查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1990267

良性前列腺增生（BPH）治疗市场：依药物类别、非专利状态、剂型及通路划分－2026-2032年全球市场预测

Benign Prostatic Hypertrophy Drugs Market by Drug Class, Generic Status, Dosage Form, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，良性前列腺增生 (BPH) 治疗市场价值将达到 58.9 亿美元，到 2026 年将增长至 62.9 亿美元，到 2032 年将达到 95.9 亿美元，复合年增长率为 7.20%。

主要市场统计数据
基准年 2025 58.9亿美元
预计年份：2026年 62.9亿美元
预测年份 2032 95.9亿美元
复合年增长率 (%) 7.20%

对重塑良性前列腺增生 (BPH) 药物治疗方法和获取趋势的临床、监管和商业性因素进行了权威概述。

本执行摘要概述了良性前列腺增生 (BPH) 药物治疗领域复杂的临床、监管和商业性环境，重点阐述了人口老化、临床指南不断更新以及供应链现状变化之间的相互作用。本文将目前的治疗现状置于药物安全性监测日益加强、专利到期以及对兼顾疗效和耐受性的联合治疗的日益关注等背景下进行分析。后续说明整合了活性成分组合、处方实践和分销模式的最新趋势，为评估政策、投资或研发决策的相关人员提供了一个统一的观点。

本文简要探讨了良性前列腺增生 (BPH) 治疗策略、取得途径和竞争格局正在发生的重大临床、商业和监管变化。

良性摄护腺增生 (BPH) 治疗市场的模式正在经历一场变革，这反映了医疗保健、药物研发和病人参与领域的更广泛变化。关键的转变包括从单一疗法模式转向联合治疗，以寻求在症状控制和疾病进展预防方面产生协同效应。同时，植物疗法证据的日趋成熟以及将真实世界证据纳入疗效比较评估，正在拓展治疗选择并影响处方行为。

评估 2025 年关税措施对良性前列腺增生 (BPH) 药物的采购、生产韧性和商业性准备的影响。

2025年关税及相关贸易政策措施的实施，进一步加剧了医药供应链的复杂性，并对生产决策、筹资策略和库存管理产生连锁反应。关税可能增加进口原料药和成品药的接收成本，迫使生产商重新评估其采购管道、优化生产基地并与供应商重新谈判合约。在价格和报销受到严格监管的地区，这些额外的成本压力可能会挤压利润空间，促使企业提高效率，并加快本地化生产以降低对外贸易摩擦的风险。

将药物类别、一般化状态、分销管道和剂型特征与处方行为、获取途径和产品策略联繫起来的详细細項分析。

治疗领域细分揭示了不同的临床和商业性动态，这对于贯穿研发、商业化和分销的策略规划至关重要。依药物类别划分，产品组合涵盖5α-还原酶抑制剂、α阻断剂、联合治疗和植物疗法。 5α-还原酶抑制剂类别的特点是具有独特的活性成分，例如度他雄胺和非那雄胺，每种成分都具有不同的药物动力学特性，并且现有的临床数据会影响处方医生的选择。 α阻断剂包括多种药物，例如阿夫唑嗪、多沙唑嗪、西洛多辛、Tamsulosin和特拉唑嗪，其选择性光谱和不利事件会影响针对特定患者表型的治疗方法。联合治疗包括5α-还原酶抑制剂与选择性α阻断剂的组合，常见的组合包括度他雄胺和Tamsulosin，以及非那雄胺和Tamsulosin。这些联合治疗旨在既能即时缓解症状，又能长期缩小前列腺体积。对于寻求辅助或替代疗法的患者，以及希望将患者意愿纳入共同决策的临床医生而言，使用β-植甾醇、非洲臀果木和锯棕榈等草药的替代疗法仍然是重要的选择。

区域概况重点介绍了监管多样性、报销框架和医疗保健基础设施如何在全球范围内造成不同的获取和采用模式。

区域差异显着影响药物的研发、核准、报销以及最终患者获得治疗的机会，每个地区都有其独特的监管、支付方和临床实践现状。在美洲，治疗方法的多样性——从公共资助的国家计画到以私人保险为主的体系——影响着谈判方式、竞标实践、药物纳入清单的时间安排，以及联合治疗和新剂型的引入。报销机制和临床指引建议相互作用，决定新证据转化为标准实务的速度。

对成熟新兴企业在产品差异化和市场定位方面所采取的竞争策略和策略措施进行分析概述。

此治疗领域的竞争动态呈现出两极化的态势：既有拥有雄厚品牌资产的老牌製药公司，也有在细分市场中寻求立足之地的灵活非专利和专科药公司。现有研发公司继续利用其临床记录、医生关係和品牌知名度，而非专利药生产商则专注于成本竞争力、稳定的供应以及与经销商和采购联盟的合作。创新体现在固定剂量组合药物的核准、缓释製剂的改进以及旨在提高患者用药依从性和持续性的患者支持服务等领域。

一系列可操作且有影响力的策略措施，旨在帮助製药公司、支付方和经销商提高良性前列腺增生症治疗方案的韧性、临床价值和可近性。

产业领导者应优先考虑一系列旨在增强韧性、临床意义和商业性差异化的措施。首先，将临床开发和上市后证据的生成与真实世界临床实践中的疗效和安全性终点相结合，可以增强产品对支付方和处方医生的价值吸引力。在常规临床实践中展示联合治疗和新製剂的具体益处，有助于将其纳入指南并获得支付方的认可。其次，优化供应链结构，减少对单一来源的依赖以及贸易相关衝击的影响，可以确保产品供应的稳定性。相关策略包括区域性生产伙伴关係、关键中间体的双重采购以及与主要经销商的联合库存管理。

对调查方法进行透明的总结，说明定性研究和二手研究的整合、资料检验技术以及局限性，以支持可重复性和策略性解释。

本报告的分析整合了多种研究途径，以确保提供可靠且可操作的见解。主要研究内容包括对临床专家、处方集决策者、采购经理和专科药剂师进行结构化访谈，以了解当前的实践模式和支付者的期望。此外，还对生产製造和供应链高管进行了访谈，以了解筹资策略和产能的考量，补充了这些定性资讯。次要研究则纳入了监管文件、临床试验註册数据和同行评审的临床文献，以全面检验疗效、安全性和指南趋势。

这是一份权威的综合分析报告，它提取了对相关人员的影响，并概述了将新趋势转化为永续的临床和商业性优势所需的策略工具。

总之，良性前列腺增生（BPH）的治疗格局正受到多种因素的共同影响而重塑。具体而言，这些因素包括临床上对联合治疗的偏好转变、监管机构对安全性和长期治疗效果日益重视，以及智慧财产权变化和供应链波动带来的商业性压力。这些趋势既给致力于在改善患者照护的同时维持永续商业模式的相关人员带来了挑战，也带来了机会。生产和供应链的韧性、策略性证据的产生以及以患者为中心的参与，将成为决定哪些产品和公司能够取得持久成功的关键因素。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 良性摄护腺增生治疗药物市场：依药物类别划分

  • 5α-还原酶抑制剂
    • 度他雄胺
    • 非那雄胺
  • α受体阻断剂
    • 阿夫唑嗪
    • 多沙唑嗪
    • 西洛多辛
    • Tamsulosin
    • 特拉唑嗪
  • 联合治疗
    • 度他雄胺+Tamsulosin
    • 非那雄胺+Tamsulosin
  • 植物疗法
    • β-谷甾醇
    • 非洲臀果木
    • 锯棕榈

第九章 良性前列腺增生（BPH）治疗药物市场：非专利现状

  • 品牌商品
    • 阿伏达特
    • 弗洛马克斯
    • 贾林
    • 保列治
  • 非专利的

第十章 良性摄护腺增生治疗药物市场分析

  • 胶囊
    • 缓释
    • 立即发布
  • 口服液
  • 药片
    • 缓释
    • 立即发布

第十一章 良性摄护腺增生治疗市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十二章 良性摄护腺增生（BPH）治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 良性摄护腺增生治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 良性摄护腺增生治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国良性摄护腺增生（BPH）治疗市场

第十六章：中国良性摄护腺增生治疗药物市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc
  • Astellas Pharma Inc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Endo Pharmaceuticals Inc
  • GlaxoSmithKline plc
  • Ipsen SA
  • Johnson & Johnson
  • Kaken Pharmaceutical Co Ltd
  • Kissei Pharmaceutical Co Ltd
  • Merck & Co Inc
  • Novartis AG
  • Pfizer Inc
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd
  • Viatris Inc
Product Code: MRR-CB04E056547E

The Benign Prostatic Hypertrophy Drugs Market was valued at USD 5.89 billion in 2025 and is projected to grow to USD 6.29 billion in 2026, with a CAGR of 7.20%, reaching USD 9.59 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.89 billion
Estimated Year [2026] USD 6.29 billion
Forecast Year [2032] USD 9.59 billion
CAGR (%) 7.20%

An authoritative orientation to the clinical, regulatory, and commercial factors reshaping therapeutic approaches and access dynamics for benign prostatic hypertrophy drugs

This executive summary introduces the complex clinical, regulatory, and commercial environment surrounding pharmacologic management of benign prostatic hypertrophy, emphasizing the confluence of aging demographics, evolving clinical guidelines, and shifting supply chain realities. It situates the therapeutic landscape within an era of intensified scrutiny over drug safety profiles, patent expirations for legacy agents, and rising interest in combination regimens that aim to balance efficacy with tolerability. The narrative that follows synthesizes recent developments in active ingredient portfolios, prescribing practices, and distribution modalities to provide a cohesive perspective for stakeholders evaluating policy, investment, or R&D decisions.

The introduction recognizes the heterogeneity of patient journeys-from initial symptom management to advanced intervention-and underscores how therapeutic choice is increasingly influenced by comorbidity management, polypharmacy concerns, and patient preferences for convenience and quality of life. Clinical guidelines continue to refine criteria for intervention, while payers and providers reassess treatment pathways to optimize outcomes and cost-effectiveness. In parallel, innovation is concentrated on improving adherence through formulation science and on identifying complementary therapies that mitigate adverse effects of standard agents. This section frames the subsequent analysis by highlighting the principal forces that are likely to drive strategic priorities across industry, clinical practice, and regulatory spheres.

A concise exploration of the pivotal clinical, commercial, and regulatory transitions that are redefining therapeutic strategies, access, and competitive dynamics for BPH treatments

The landscape for benign prostatic hypertrophy therapeutics has undergone transformative shifts that reflect broader changes across healthcare delivery, drug development, and patient engagement. Key shifts include a move from single-agent paradigms toward combination strategies that seek synergistic gains in symptom control and disease progression mitigation. This is complemented by a parallel maturation of evidence around phytotherapeutic options and the integration of real-world evidence into comparative effectiveness assessments, which together broaden therapeutic choice and influence prescribing behavior.

Another transformative element is the rapid digitization of the patient journey, which has altered how prescriptions are accessed, refilled, and monitored. Telehealth consultations and digital adherence tools are increasingly common, prompting manufacturers and distributors to re-evaluate channels for patient support programs and post-marketing surveillance. Regulatory environments have also evolved, with authorities emphasizing pharmacovigilance and clearer benefit-risk communication, particularly for agents with long-term exposure in older populations. In addition, intellectual property transitions and the rise of high-quality generics are intensifying competition and prompting lifecycle strategies focused on formulation improvements, combination approvals, and line extensions. Collectively, these shifts compel manufacturers, payers, and clinicians to reassess clinical value propositions and to prioritize interventions that demonstrably improve long-term patient outcomes while maintaining affordability and access.

An assessment of how 2025 tariff measures influenced pharmaceutical sourcing, manufacturing resilience, and commercial readiness for benign prostatic hypertrophy therapeutics

The imposition of tariffs and related trade policy measures in 2025 introduced incremental complexity into the supply chain for pharmaceuticals, with cascading effects on manufacturing decisions, procurement strategies, and inventory management. Tariffs can increase landed costs for imported active pharmaceutical ingredients and finished dosage forms, prompting manufacturers to review sourcing options, re-optimize production footprints, and renegotiate supplier contracts. In jurisdictions where pricing and reimbursement are tightly regulated, these added cost pressures can compress margins, catalyze efficiency drives, and accelerate efforts to localize manufacturing to reduce exposure to external trade friction.

Beyond direct cost implications, tariffs have also influenced the cadence of regulatory submissions and contract negotiations. Procurement officers and health systems have increasingly factored geopolitical risk into multi-year supplier agreements and contingency planning, driving a preference for diversified supplier networks and buffer inventories. For manufacturers, the response has included greater emphasis on supply chain resilience through dual sourcing, strategic stockpiling of critical intermediates, and investment in regional production capabilities. Importantly, these adaptations affect more than cost lines; they shape product availability, launch sequencing for new formulations or combination therapies, and the competitive landscape as some firms are better positioned to absorb or mitigate tariff-related disruptions. In sum, tariff dynamics in 2025 acted as an accelerant for strategic realignment across sourcing, manufacturing, and commercialization decisions within the therapeutic area.

In-depth segmentation narrative linking drug classes, generic status, distribution channels, and dosage form attributes to prescribing behavior, access pathways, and product strategies

Segmentation of the therapeutic domain reveals differentiated clinical and commercial dynamics that are essential for strategic planning across development, commercialization, and distribution. Based on drug class, the portfolio spans 5-alpha reductase inhibitors, alpha blockers, combination therapy, and phytotherapy. The 5-alpha reductase inhibitors category is characterized by distinct active molecules such as dutasteride and finasteride, each with divergent pharmacokinetic properties and legacy clinical data that influence prescriber choice. Alpha blockers encompass a spectrum of agents including alfuzosin, doxazosin, silodosin, tamsulosin, and terazosin, where selectivity profiles and adverse event considerations drive therapeutic selection for specific patient phenotypes. Combination therapy options pair a 5-alpha reductase inhibitor with a selective alpha blocker, with commonly observed pairings involving dutasteride plus tamsulosin and finasteride plus tamsulosin; these combinations are positioned to address both immediate symptom relief and longer-term prostate volume reduction. Phytotherapeutic alternatives-such as beta-sitosterol, pygeum, and saw palmetto-remain relevant for patients seeking complementary or alternative approaches and for clinicians who integrate patient preference into shared decision-making.

Based on generic status, the landscape comprises both branded and generic offerings, with branded agents including noted trade names that have historically shaped prescribing habits and promotional approaches. Patent expirations and the ensuing generic entries have prompted lifecycle management strategies among originators, including reformulation, indication consolidation, and patient support initiatives. Based on distribution channel, treatment access is mediated through hospital pharmacies, online pharmacies, and retail pharmacies; each channel has its own dynamics around procurement cycles, patient counseling opportunities, and reimbursement interactions. Based on dosage form, therapeutic presentations include capsules, oral solutions, and tablets, with formulations differentiated by release profile-capsules and tablets are available in extended release and immediate release variants-affecting adherence, dosing convenience, and tolerability profiles. Recognizing these segmentation nuances is critical for aligning product development, commercial messaging, and distribution strategies with clinician needs and patient expectations.

A regional synthesis highlighting how regulatory diversity, reimbursement frameworks, and healthcare infrastructure drive distinct access and adoption patterns across global territories

Regional differences materially shape how therapies are developed, approved, reimbursed, and ultimately accessed by patients, with each geographic area presenting distinct regulatory, payer, and clinical practice realities. In the Americas, healthcare systems vary from publicly funded national programs to predominantly private insurance frameworks, influencing formulary negotiation approaches, tendering practices, and the adoption timeline for combination therapies and novel formulations. Reimbursement mechanisms and clinical guideline endorsements interact to determine how quickly new evidence is translated into changes in standard practice.

In Europe, the Middle East & Africa region, a mosaic of regulatory regimes and reimbursement environments requires tailored market access strategies that account for divergent price controls, varying levels of pharmacovigilance infrastructure, and differing capacities for local manufacturing. This complexity often necessitates regionalized clinical evidence generation and adaptive commercial models that reflect the heterogeneity of payer expectations. In the Asia-Pacific region, high population growth, increasing healthcare investment, and accelerating digital health adoption are creating fertile conditions for expanded access models, greater emphasis on cost-effective generics, and the rapid scaling of e-prescription and online pharmacy channels. Across all regions, local clinical guidelines, demographic trends, and supply chain capabilities are primary determinants of product uptake and long-term positioning.

An analytical overview of competitive approaches and strategic maneuvers by incumbent and emerging companies shaping product differentiation and market positioning

Competitive dynamics in this therapeutic area reflect a mix of established pharmaceutical firms with legacy branded assets and agile generic manufacturers and specialty companies pursuing niche positioning. Incumbent originator companies continue to leverage clinical legacy, physician relationships, and brand recognition, while generics manufacturers focus on cost competitiveness, reliable supply, and partnerships with distributors and procurement consortia. Innovation is observable in areas such as fixed-dose combination approvals, reformulated extended-release products, and patient support services designed to improve adherence and persistence.

Strategic collaborations and licensing arrangements are increasingly prominent as a way to accelerate geographic expansion and to share risk related to manufacturing localization or regulatory submissions. Companies that invest in clinical evidence demonstrating improved outcomes with combination regimens or novel formulations tend to achieve stronger clinician buy-in. At the same time, those that can integrate digital support tools, curated educational content for prescribers, and real-world data capture into their go-to-market strategies create differentiated value propositions that extend beyond price-focused competition. The interplay between brand stewardship and cost-effective manufacturing capability will remain central to competitive performance in the near term.

A set of practical, high-impact strategic moves for manufacturers, payers, and distributors to strengthen resilience, clinical value, and uptake of BPH treatment options

Industry leaders should prioritize a portfolio of actions designed to enhance resilience, clinical relevance, and commercial differentiation. First, aligning clinical development and post-marketing evidence generation with real-world effectiveness and safety endpoints will strengthen value narratives with payers and prescribers. Demonstrating tangible benefits of combination regimens or new formulations in routine care settings will facilitate guideline incorporation and payer acceptance. Second, optimizing supply chain architecture to reduce exposure to single-source dependencies and trade-related shocks will protect product availability; strategies include regional manufacturing partnerships, dual sourcing of key intermediates, and collaborative inventory management with major distributors.

Third, investment in digital patient engagement and adherence technologies should be treated as a core component of product launch and lifecycle programs rather than an adjunct activity, because these tools can materially improve persistence and support outcome-based contracting. Fourth, tailored access strategies that reflect regional regulatory and reimbursement realities-ranging from evidence packages for health technology assessment committees to flexible pricing arrangements-will be essential to unlocking adoption across diverse jurisdictions. Finally, companies should explore targeted alliances with clinical centers and professional societies to co-create educational initiatives that address appropriate patient selection and long-term management, thereby elevating both clinical practice and product uptake.

A transparent methodological synopsis describing qualitative and secondary research integration, data validation approaches, and limitations to support reproducibility and strategic interpretation

The analysis underpinning this report synthesizes multiple research approaches to ensure robust, actionable insights. Primary research elements included structured interviews with clinical experts, formulary decision-makers, procurement leads, and specialty pharmacists to capture contemporary practice patterns and payer expectations. These qualitative inputs were complemented by targeted interviews with manufacturing and supply chain executives to understand sourcing strategies and capacity considerations. Secondary research incorporated regulatory documents, clinical trial registries, and peer-reviewed clinical literature to triangulate efficacy, safety, and guideline trends.

Data integrity was maintained through cross-validation of stakeholder claims against publicly available regulatory communications and clinical evidence. The methodology emphasized transparency in assumptions and documented limitations, including recognition of geographic variability in data availability. Where applicable, synthesis prioritized recent peer-reviewed findings and government-issued guidance to reflect current standards of care and regulatory priorities. Throughout the research process, ethical considerations guided outreach and data handling, and methodological choices were designed to support reproducibility and relevance to strategic decision-making.

A conclusive synthesis that distills implications for stakeholders and outlines the strategic levers necessary to convert emerging trends into sustainable clinical and commercial advantages

In conclusion, the therapeutic landscape for benign prostatic hypertrophy is being reshaped by convergent forces: clinical preferences shifting toward combination strategies, regulatory emphasis on safety and long-term outcomes, and commercial pressures arising from intellectual property transitions and supply chain volatility. These dynamics create both challenges and opportunities for stakeholders seeking to advance patient care while maintaining sustainable commercial models. Resilience in manufacturing and supply, strategic evidence generation, and patient-centric engagement will be the differentiators that determine which products and companies achieve durable success.

Looking ahead, organizations that proactively adapt to regional regulatory nuances, integrate digital adherence solutions, and align clinical development with real-world outcomes will be best positioned to influence standards of care and secure durable partnerships with payers and healthcare systems. Cross-functional collaboration-linking R&D, regulatory affairs, supply chain, and commercial teams-will be essential to translate insight into execution and to ensure that innovations meaningfully improve patient experiences and clinical endpoints.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Benign Prostatic Hypertrophy Drugs Market, by Drug Class

  • 8.1. 5-Alpha Reductase Inhibitors
    • 8.1.1. Dutasteride
    • 8.1.2. Finasteride
  • 8.2. Alpha Blockers
    • 8.2.1. Alfuzosin
    • 8.2.2. Doxazosin
    • 8.2.3. Silodosin
    • 8.2.4. Tamsulosin
    • 8.2.5. Terazosin
  • 8.3. Combination Therapy
    • 8.3.1. Dutasteride + Tamsulosin
    • 8.3.2. Finasteride + Tamsulosin
  • 8.4. Phytotherapy
    • 8.4.1. Beta-Sitosterol
    • 8.4.2. Pygeum
    • 8.4.3. Saw Palmetto

9. Benign Prostatic Hypertrophy Drugs Market, by Generic Status

  • 9.1. Branded
    • 9.1.1. Avodart
    • 9.1.2. Flomax
    • 9.1.3. Jalyn
    • 9.1.4. Proscar
  • 9.2. Generic

10. Benign Prostatic Hypertrophy Drugs Market, by Dosage Form

  • 10.1. Capsule
    • 10.1.1. Extended Release
    • 10.1.2. Immediate Release
  • 10.2. Oral Solution
  • 10.3. Tablet
    • 10.3.1. Extended Release
    • 10.3.2. Immediate Release

11. Benign Prostatic Hypertrophy Drugs Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Benign Prostatic Hypertrophy Drugs Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Benign Prostatic Hypertrophy Drugs Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Benign Prostatic Hypertrophy Drugs Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Benign Prostatic Hypertrophy Drugs Market

16. China Benign Prostatic Hypertrophy Drugs Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc
  • 17.6. Astellas Pharma Inc
  • 17.7. Bayer AG
  • 17.8. Boehringer Ingelheim International GmbH
  • 17.9. Bristol-Myers Squibb Company
  • 17.10. Eli Lilly and Company
  • 17.11. Endo Pharmaceuticals Inc
  • 17.12. GlaxoSmithKline plc
  • 17.13. Ipsen S.A
  • 17.14. Johnson & Johnson
  • 17.15. Kaken Pharmaceutical Co Ltd
  • 17.16. Kissei Pharmaceutical Co Ltd
  • 17.17. Merck & Co Inc
  • 17.18. Novartis AG
  • 17.19. Pfizer Inc
  • 17.20. Sanofi S.A
  • 17.21. Sun Pharmaceutical Industries Ltd
  • 17.22. Teva Pharmaceutical Industries Ltd
  • 17.23. Viatris Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALFUZOSIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALFUZOSIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALFUZOSIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOXAZOSIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOXAZOSIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOXAZOSIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SILODOSIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SILODOSIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SILODOSIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TAMSULOSIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TAMSULOSIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TAMSULOSIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TERAZOSIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TERAZOSIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TERAZOSIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE + TAMSULOSIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE + TAMSULOSIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE + TAMSULOSIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE + TAMSULOSIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE + TAMSULOSIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE + TAMSULOSIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BETA-SITOSTEROL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BETA-SITOSTEROL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BETA-SITOSTEROL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PYGEUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PYGEUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PYGEUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SAW PALMETTO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SAW PALMETTO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SAW PALMETTO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY AVODART, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY AVODART, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY AVODART, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FLOMAX, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FLOMAX, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FLOMAX, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY JALYN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY JALYN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY JALYN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PROSCAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PROSCAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PROSCAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ORAL SOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ORAL SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ORAL SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. GCC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. GCC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 221. GCC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 222. GCC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 223. GCC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 224. GCC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 225. GCC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
  • TABLE 226. GCC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 227. GCC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 228. GCC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 229. GCC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 230. GCC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 255. G7 BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. G7 BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 257. G7 BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 258. G7 BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 259. G7 BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 260. G7 BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 261. G7 BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
  • TABLE 262. G7 BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 263. G7 BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 264. G7 BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 265. G7 BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 266. G7 BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 267. NATO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 268. NATO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 269. NATO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 270. NATO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 271. NATO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 272. NATO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 273. NATO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
  • TABLE 274. NATO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 275. NATO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 276. NATO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 277. NATO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 278. NATO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 279. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018